
SYDRA is a biotech company focused on discovering novel geroprotectors using a state-of-the-art closed loop discovery platform that combines advanced Artificial Neural Networks (ANN) with autonomous robotic in vivo screening. Their innovative approach aims to combat the hallmarks of aging, enhancing life quality and lifespan expectancy. With a strong emphasis on deep AI and data science, SYDRA leverages tailored AI models for drug discovery, significantly reducing development time and costs. The company is positioned at the forefront of biogerontology, targeting a positive impact on human health and longevity.

SYDRA is a biotech company focused on discovering novel geroprotectors using a state-of-the-art closed loop discovery platform that combines advanced Artificial Neural Networks (ANN) with autonomous robotic in vivo screening. Their innovative approach aims to combat the hallmarks of aging, enhancing life quality and lifespan expectancy. With a strong emphasis on deep AI and data science, SYDRA leverages tailored AI models for drug discovery, significantly reducing development time and costs. The company is positioned at the forefront of biogerontology, targeting a positive impact on human health and longevity.
Founded: 2024
Headquarters: Schlieren, Zurich, Switzerland
Focus: AI-driven discovery of geroprotectors with autonomous in vivo screening
Notable funding: Convertible Note (Jan 22, 2024) led by EWOR
Biogerontology / longevity therapeutics discovery
2024
Biotechnology
“EWOR as lead investor and recipient of a VentureKick Stage I grant”